TrialBlood2015

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

David T Yeung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.